CN1481804A - Eye nutrients formulation for prevention and cure of age-related cataract, macula lutea degradation and other eye disease , and its application method - Google Patents
Eye nutrients formulation for prevention and cure of age-related cataract, macula lutea degradation and other eye disease , and its application method Download PDFInfo
- Publication number
- CN1481804A CN1481804A CNA021485887A CN02148588A CN1481804A CN 1481804 A CN1481804 A CN 1481804A CN A021485887 A CNA021485887 A CN A021485887A CN 02148588 A CN02148588 A CN 02148588A CN 1481804 A CN1481804 A CN 1481804A
- Authority
- CN
- China
- Prior art keywords
- zeaxanthin
- rutin
- prescription
- macula lutea
- age
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Abstract
The present invention is one group of carotenoid antioxidant recipe comprising lutin and/or rutin ester, zeaxanthin and/or zeaxanthin ester and other antioxidant. Several medicinal and health care antioxidant products may be produced to avoid, delay or treat the harmful effect of the free radical caused by light, cigarette and hormone to eye, especially its crystalline lens and retina. The present invention is used mainly for the prevention and treatment of age relevant eye diseases, cataract, macular degeneration, etc. Dihydroxy carotenoid and other antioxidant are used to nourish crystalline lens and retina so as to enhance the capacity of eye, especially its crystalline lens and retina, in resisting the effect of outer negative factors.
Description
Technical field
The present invention uses dihydroxy carotenoid, vitamin C, vitamin E and other antioxidant so that eye lens and retina obtain necessary nutrition, oculopathy, especially cataract and degeneration of macula that realization delays, prevention is relevant with the age with treatment.The invention belongs to eye care and treatment field.
Background technology
Eye's lens be a biconvex, transparent, free retractility structure is arranged, we can optionally see clearly nearby or distant objects, all have benefited from freely changing according to the vision needs crystalline lens of shape.By this change, light can focus on the retina exactly.
Lenticular major part is a lens fibers albumen.Lens fibers albumen is built together as the tight bag of Bulbus Allii Cepae.Lenticular structure makes that crystalline lens is transparent, but it has still absorbed the ultraviolet that most of wavelength is shorter than 400nm.Lenticular this defencive function has prevented that effectively wavelength is shorter than the phototoxicity destruction of the ultraviolet of 400nm to eye retina.
This protection is not have cost.In fact, intensive oxidation and antioxidation battle are taking place in crystalline lens inside.There are some researches show that ascorbic concentration is tens of times of vitamin C concentration in the blood unexpectedly in the crystalline lens.Except vitamin C, also have rutin, zeaxanthin and these three kinds of antioxidants of vitamin E in the crystalline lens.
Owing to formed by protein, so intensive ultraviolet, especially UVB are to play injury effect to crystalline lens by ultraviolet heat, machinery or photochemistry mechanism.Certainly ultraviolet depends primarily on the degree of protection of its wavelength, power, open-assembly time and antioxidant to lenticular degree of injury.In general, we should not observe and learn the suffered this injury of crystalline lens by experience in the short time.But along with the growth at our age, our lenticular volume increases gradually, density increases and the elasticity variation.This causes us can see very nearby thing like that clearly not as the child gradually, presbyopic symptom occurred generally being referred to as.
Except the growth at age mean crystalline lens the cumulative unfavorable factor of the photodamaged that may be subjected to; the growth at age is being represented the enzyme that eyes is had protective effect toward contact, as weakening of glutathione peroxidase, glutathion reductase, catalyzing enzyme and superoxide dismutase function.
Yet crystalline lens degeneration, old and feeble more immediate cause may be that its internal layer lens fibers albumen can not obtain enough nutrition, and metabolic change has caused oxidation.
Undoubtedly, the presbyopia has brought painful and inconvenient to the life of stepping into old crowd from the middle age.Usually presbyopia is just to taste career and family " people in middle age " people observes and learns first signal of aging by experience.
Concerning many middle-aged and elderly people, lenticular variation may will rest on presbyopia's stage with age growth caused, although the degree of presbyopia can because of the time different, more vary with each individual.But concerning a part of middle-aged and elderly people, lenticular variation may develop into lenticular atomizing.This makes the thing seen all be out of shape, as through clouded glass.Most cataract all is because of due to caused crystalline lens hardening of age, thickening, density increases.This dependency from cataractous sickness rate and age (the over-65s old man of the U.S. eyes institute report U.S. 50% suffers from cataract) can be caught a glimpse of.
Cataract is not only the modal oculopathy of U.S. old man, also is one of easily blind most important reason of old man.Data shows that about 50% is from the cataract of not performing an operation among the whole world 50,000,000 blind patients.
Its Chronological Age is one of cataractous key factor.In fact smoke, often be exposed under the sunburst that is rich in ultraviolet, especially UVB, and lack enough antioxidants in the diet, can increase the danger that cataract takes place greatly.In addition, cataract usually is second symptom of diabetics except that hyperglycemia.
China is cigarette consumption big country, and not only the smoker is many, and " the lifelong smoker " that just smoke from teenager also quantity is surprising.Evidence suggests that the smoker sucks a large amount of peroxide.The content of peroxide of fat is all high in smoker's blood and in the exhalation thing.Rutin, zeaxanthin etc. and eyes key health have the carotenoid of substantial connection and Vitamin C content all on the low side in smoker's blood in addition.These may mean that all smoking has weakened antioxidant to lenticular defencive function.
For being rich in ultraviolet sunburst, we must mention the western plateau that China is representative with the Tibet plateau.
Tibet is a jewel of China.The there except have abundant underground heat, the ore resources, its special tourist resources has been created some the first in the world especially.There is highest peak in world in Tibet, the highest in the world plateau is arranged, male in the world dangerous Yarlungzangbo Grand Canyon is arranged, the multiformity of the most peculiar vertical distribution view, the environment that minimum pollution is in the world arranged and biology and environment is arranged in the world.Along with Qinghai-Tibet Railway be about to be open to the traffic, the high speed development in Tibet is within sight.
Yet height above sea level is high especially just, air is thin especially, makes that the ultraviolet in the sunlight is strong especially, and for these years, this noiseless killer does not know to cause and causing thousands of blood brother because of losing one's sight that cataract causes.Really, modern ophthalmology technology can be taken out fuzzy crystalline lens with operating method when cataract develops into vision and is subjected to serious hindrance, replant into prosthetic lens.But this operation one comes the expense costliness.It is reported that the Medicare in America health care will spend about 3,500,000,000 dollars every year, is used for about 1,300,000 routine cataract operations.The secondth, this operation is often implemented when patient's vision has been subjected to serious obstruction, and patient's quality of life is greatly affected.And two eyes traditionally, can only separately do, every day, eyes all will have the postoperative of certain hour to adjust the phase.The 3rd is still to have 10% corrective surgery can not improve vision approximately.
Except intensive ultraviolet, lacking enough antioxidants in the diet also may be the extra high another major reason of Tibet region cataract incidence.Tibet is extremely frigid zones, and frost-free period is short.If do not adopt modern agricultural technology, the fresh green vegetable and the fruit that are rich in antioxidant are difficult for growth.And having inconvenient traffic between the interior ground gone into to hide for again other local fruit and vegerable of the whole nation and added inconvenience.
Can increase cataractous sickness rate since lack enough antioxidants in the diet, whether this means that antioxidant can protect eye lens and and then reduce cataractous sickness rate.
Stand in today on the starting line of development of the West Regions, medical worker has a responsibility for, obligated the most lovable people for exploitation Tibet, defendance Tibet, for all go Tibet people's exploration, develop a kind of easy, effectively delay, prevent or treat cataractous method.
Although remain developing country, aging city ranks have been stepped into as Shanghai in some areas of China.Eyes we can say how to emphasize also not for undue to the importance of people's health again.Keeping good vision of old people is to improve an extremely important aspect of life of elderly person quality.
Threaten old human eye health except that cataract, macula lutea decline (age related maculardegeneration) also is the one of the main reasons of global over-65s old man visual loss.According to statistics, the age, macula lutea decline patient in 43 years old to 64 years old crowd only accounted for 15%.On the contrary, 85% patient is arranged at 65 years old or over-65s age bracket.
Macula lutea is positioned at the anatomical center that view is touched, and is people's center of vision, owing to be positioned at the center of retina recess, is the place of sight line axle and retina intersection here.Macula lutea therefrom mind-set is expanded the about 2.75mm of radius outward.The yellow of ' macular pigment ' owing to have is so this zone is easy to identification.
In fact macular pigment is distributed in whole retina, but with the Huang point place concentration at macula lutea center for the highest.Macular pigment that there are some researches show human body is made up of rutin, these two kinds of dihydroxy carotenoid of zeaxanthin.The zeaxanthin and the rutin concentration at yellow some place, macula lutea center are the highest, and weaken with the increase of distance centre distance.For example the amount of the dihydroxy carotenoid of recess center per unit retina area is 1.33ng/mm
2, and just weaken to 0.88ng/mm apart from center 1.6-2.5mm place
2Compare with other carotenoid, rutin and zeaxanthin are many two hydroxyls, also there are three kinds of possible stereoisomers in zeaxanthin.
Age, relevant macula lutea decline can be divided into two types haply.Account for the atrophy that 90% dryness disease is presented as the zone, it is characterized in that the deposit of hard or soft cell debris.Choroidal neovascularization can appear in moist disease more a little later, the disengagement of retinal pigment epithelium, inferior retinal hemorrhage, or retinal scar.
Studies show that relevant macula lutea decline of age is relevant to the infringement of macula lutea photoreceptor with light.Macular region has the taper photoreceptor of being responsible for acute vision function.And this exactly taper photoreceptor more is easy to be destroyed by visible light than shaft-like photoreceptor.With advancing age, this quantitative change that macula lutea destruction is accumulated over a long period finally can be converted into the organic sudden change of macula lutea decline.
The pharmaceutical research that animal is carried out shows that oxidation mechanism can cause cataract and macula lutea decline.In crystalline lens, the active oxygen (reactive species of oxygen) that is produced by photooxidation or metabolic process can cause damage to following three kinds of components: (1) crystallin; (2) tunica fibrosa lentis and (3) enzyme.Active oxygen then may be promoted the peroxidating of the unsaturated fatty acid that the photoreceptor outer membrane is rich in for retina.No matter in fact be crystalline lens or retina, they are subjected to the probability of photooxidation all is very big.Because they just are exposed in light and the oxygen enriched environment itself.Report is arranged, and the rising of oxygen is associated with the decline of damage threshold and more serious damage in the blood.Oxygen strengthens blue light and damages the toxicity combination that the basic mechanism of having pointed out photochemical damage is light and oxygen.
The process of chain reaction can take place or end by inhibition or delayed response in antioxidant, and changes autoxidizable dynamic process dramatically.On the mechanism of action, antioxidant can be divided into two kinds of inhibitor and blocker.Antioxidant can work by following manner: (1) is by eliminating or reduce the amount of initiator or chain reaction intermediate product; (2) as light absorber; (3) as peroxide decomposer and (4) as radical scavenger.
For the systematic study antioxidant to relevant possible prevention and the therapeutical effect of oculopathy of age, American National eyes institute in nineteen ninety JIUYUE started by name " research of age associated ophthalmopathy " (Age-Related Eye Disease Study, multi-center clinical trial plan AREDS).This research is still in process so far, but the phasic results that national eyes institute has been issued this research in October 12 calendar year 2001, spell out the high concentration antioxidant and the danger of relevant macula lutea decline of age in late period can be reduced by 25% with zinc, the blind rate due to the health product of same prescription also can fail relevant macula lutea of age in late period reduces 19%.But this prescription does not make significant difference to cataract.
" research of age associated ophthalmopathy " used antioxidant and trace element prescription are as follows:
1. vitamin C 500mg
2. vitamin E 400 ius
3. 15'-dioxygenase mg
4. zinc 80mg
5. copper 2mg
Regrettably, because the horizontal constraints of the research of the eye care before more than ten years, " research of age associated ophthalmopathy " employed antioxidant prescription contains vitamin C, vitamin E, beta-carotene, zinc and copper, and does not have rutin and zeaxanthin.Effect that such prescription is invalid to cataract, macula lutea fails well result is no wonder.
However, this prescription is still the at present best eye care prescription of the U.S..Once release, the annual sales amount of a brand that only with Ocuvite is trade name is just above 40,000,000 dollars.
Summary of the invention
The objective of the invention is to seek an a kind of class and be used for the prevention of oculopathy such as relevant cataract of age, macula lutea decline and the eye nutrient prescription and the using method thereof of treatment.。
Another object of the present invention is to prevent with the increase that delays crystalline lens density and the density that keeps the macula retinae pigment or treat because of cataract and senile oculopathy such as macula lutea decline and presbyopia due to the age by replenishing rutin, zeaxanthin and/or other antioxidant that crystalline lens and retina contained.
Further purpose of the present invention provide the new prescription that contains rutin, zeaxanthin and/or other antioxidant and other health care or medicinal component with prevention and treatment because of cataract and senile oculopathy such as macula lutea decline and presbyopia due to the age.
Main technical schemes of the present invention is to contain rutin and zeaxanthin in this prescription.
The using method of the eye nutrient prescription of a kind of prevention that is used for oculopathy such as relevant cataract of age, macula lutea decline and treatment; it is characterized in that providing the rutin of q.s or/and zeaxanthin by oral or topical or other route of administration; with rutin in the lifting blood or/and the concentration of zeaxanthin; to being equal to or higher than the macula retinae rutin or/and zeaxanthin deposits needed level; and kept for 4 to 8 weeks;, can suspend or use than low dosage and kept or/and after zeaxanthin concentration returns to expected value when rutin in the macula lutea.
Every day used rutin or/and the accumulated dose of zeaxanthin between 1.0mg to 50mg.Perhaps every day used rutin or/and the accumulated dose of zeaxanthin between 2.0mg to 25mg.About 5: 1 of the ratio of rutin and zeaxanthin.Take rutin every day or/and the accumulated dose of zeaxanthin by per kilogram of body weight between the 0.05mg to 5mg.Described rutin is or/and zeaxanthin is free type, or corresponding ester.
Rutin in the described prescription is or/and zeaxanthin is pharmaceutical formulation or health product or fast-food type functional food.Described prescription also can be a kind of by rutin or/and zeaxanthin or/and its ester and other are medicinal or food with the mixture of raw material, adjuvant or carrier.
At least contain a kind of antioxidant at above-mentioned pharmaceutical formulation or health product or fast-food type functional food.
Described prescription can be loose the side or with unit dosage form for use.
Described antioxidant be vitamin A or/and vitamin C or/and vitamin E or/and Semen Cassiae or/and Flos Chrysanthemi or/and Flos Chrysanthemi Indici or/and Fructus Lycii or/and Fructus Atriplicis Sibiricae or/and Herba Spinaciae.
Described antioxidant for referring to except that rutin or/and other carotenoid the zeaxanthin, as: lycopene or/and α carotene or/and bata-carotene or/and γ carotene or/and δ carotene.
Unit dosage form can be the fast food functional food of tablet or capsule or drop or pill or powder or unguentum or cream or solution or suspensoid or opacifiers or injection or implant or patch or liniment or spray or arbitrary form.
In known about 400 kinds of carotenoid, beta-carotene is that people study at most, thereby also is be accustomed to using most a kind of.Yet concerning keeping normal eye function, rutin and zeaxanthin are only two kinds of carotenoid of most critical.These two kinds of polar compounds are topmost carotenoid in the macula lutea.And nonpolarly all be not present in the macula lutea as beta-carotene and lycopene etc.Similar with the situation of macula lutea, do not have beta-carotene in the crystalline lens yet, and mainly be rutin and zeaxanthin.
Different with other nonpolar carotenoid with beta-carotene is, rutin and zeaxanthin separately have special importance aspect the physiologically active at two hydroxyls of two ends.The test of phospholipid model confirms that two hydroxyls of zeaxanthin make the zeaxanthin molecule almost completely then stay water perpendicular to the membrane plane hydroxyl.And same test confirms that beta-carotene can only vertical, the partial parallel of part.The combination well between the two of the latter's position description, this influences its physiologically active certainly.The test of antioxygenic property has also proved that rutin and zeaxanthin are better than beta-carotene.For example rutin more can suppress the autoxidation of the fat in the cultured cells effectively than beta-carotene, and zeaxanthin is stronger by about 50% than beta-carotene aspect the oxidation that delays liposome.No wonder the eye lens of non-stop run and retina have selected rutin and zeaxanthin rather than beta-carotene to make antioxidant under light and oxygen enriched environment.Although the latter has been extremely excellent antioxidation agent.
It is directly related with cataract and macula lutea decline to the particularly important is rutin and zeaxanthin.There are some researches show the old people more than 60 years old if macula retinae pigment (referring to rutin and zeaxanthin) density is hanged down then weak-eyed, its probability of suffering from macula lutea decline is just big.On the contrary, the height of rutin and zeaxanthin density is not relevant with the age in the macula lutea really, and is widely different between the Different Individual as long as high its visual acuity of crowd of macular pigment density is still similar with youngster the same age.Individual on the contrary chronic dietary custom is the deciding factor of macula retinae pigment density size.
But the density of rutin and zeaxanthin is directly related with the macula lutea decline really in the macula lutea.The content of analytical proof macula lutea decline patient retina rutin and zeaxanthin hangs down 30% approximately than the normal person.What is interesting is that rutin and zeaxanthin content are directly related in cataractous sickness rate and the macula lutea.The research report is arranged, for the old people, the concentration relation of being inversely proportional to of eye lens density and macula lutea rutin and zeaxanthin.If this means that rutin and zeaxanthin are on the low side in old people's the macula lutea, then crystalline lens density will increase.And the increase of crystalline lens density is cataractous principal character.
This shows that no matter from the macula lutea decline or from the cataract angle, a certain amount of rutin and zeaxanthin are extremely important to old people's eye health in the maintenance eyes macula lutea.
Human body can not self synthesize rutin and zeaxanthin, and unique method is to take in or take in its precursor compound.The present invention makes health product or medicine with rutin and/or zeaxanthin exactly, and the amount with rutin and zeaxanthin in increase and the maintenance macula retinae delays, prevents cataract relevant with the treatment age and macula lutea decline thereby reach.Rutin among the present invention, zeaxanthin can use separately, also can with suitable health care of food with or pharmaceutic adjuvant together use, can also merge with other antioxidant such as vitamin C, vitamin E and trace element or plant extract and use.Rutin used in the present invention and/or zeaxanthin can be that free type also can be its fat.Zeaxanthin can be a kind of, the wantonly two kinds mixture in three kinds of isomers, also can be three kinds mixture.
The preparation that contains rutin and/or zeaxanthin of the present invention can oral administration be taken in, and also can splash into, be coated with or implant through the eyes part.
When oral, every day used rutin and/or zeaxanthin total amount between 1.0mg to 50mg.In general, should be between 2.0mg to 25mg, and optimum range should be between 5-20mg.Actual employed dosage should be decided according to the order of severity of relevant cataract of age and macula lutea decline.When if patient's macula retinae has not almost had rutin and zeaxanthin, use the amount of higher relatively (suggestion amount 25mg/ days) possibly.In addition, weight in patients also influences the total amount of oral rutin and/or zeaxanthin.Should be between 0.05 to 0.5mg by per kilogram of body weight.
Containing taking of rutin and/or zeaxanthin preparation can be divided into the additional phase of acceleration and keep two stages of phase.In general, at the use initial stage, suggestion adopts higher dosage (as 25mg/ days) or oral and local use to carry out simultaneously.And when rutin in the macula lutea and zeaxanthin rise to a stabilised platform, can use lower amount (as 5-10mg/ days) or only use topical or only use long-acting implantation preparation.So the present invention includes high dose oral preparation and low dose oral preparation, local administration preparation and long-acting implantation preparation.
Preparation of the present invention can also comprise except that comprising rutin and zeaxanthin:
Semen Cassiae extract, Flos Chrysanthemi extract, Flos Chrysanthemi Indici extract, Fructus Lycii extract, Fructus Atriplicis Sibiricae extract, Spinach extract, beta-carotene, lycopene, vitamin A, vitamin C, vitamin E, selenium, zinc, copper, manganese, ubiquinone
10And glutathion.
The present invention's prescription can be the square formula of loosing, and also can be unit dosage form.The present invention's prescription can manufacture tablet, capsule, and drop, pill, powder, unguentum, cream, solution, suspensoid, opacifiers, various injections, implant, patch, liniment, spray also can be the fast food of arbitrary form.
The present invention's prescription can use varieties of food items, health product or pharmaceutical production technology to carry out food or preparation processing.Corresponding food and preparation can be selected medicinal or edible adjuvant, condiment or the material that meets country pharmacopeia, food standard or relevant regulations for use according to the character of active constituent, object and the function that preparation uses.
The present invention's prescription can be with tablet, capsule, and drop, pill, powder, unguentum, cream, solution, suspensoid, opacifiers, injection, implant, patch, liniment, the fast food functional food of spray or arbitrary form uses.The use approach can oral administration, or through eyes splash into or be coated with, injection, skin penetrates or implant through the eyes local subcutaneous.
Beneficial effect compared with prior art
In the background technology can with macula lutea decline dangerous reduce by 25% prescription represent the current U.S. so that in the world with age associated ophthalmopathy prevention in preferably prescription.By comparison, the present invention has replaced beta-carotene with rutin and zeaxanthin.This replacement, brought following benefit at least:
1, all be rutin and zeaxanthin with cataract and the macula lutea contained carotenoid of closely-related crystalline lens and macula lutea that fails, rather than beta-carotene.Illustrate that rutin and zeaxanthin are more important to crystalline lens and macula lutea.
2, the density of rutin and zeaxanthin height and cataract and macula lutea decline height correlation in old people's macula lutea.Beta-carotene is not deposited such dependency relation.
3, rutin and zeaxanthin are than more excellent antioxidation agent of beta-carotene, thereby can protect eyes better.
4, the prescription of background technology can only reduce by 25% with the danger of macula lutea decline, and cataract there is not the significance effect, but often edible be rich in rutin and its macula lutea decline danger of zeaxanthin green vegetable crowd and can be reduced to closely 80%, and cataractous danger then reduces by 47%.The present invention also has improvement in the following areas in addition:
5, released whole body and the local different dosage form that uses, increased fast food sexual function food, made the user that more more options be arranged, used convenient, safe, effective.
6, having increased 1,100 medicine practices proves the Chinese herbal medicine extract that eyes is had the care effect, can produce synergism.
Description of drawings
Fig. 1 is the stereochemical structure of rutin and three isomers of zeaxanthin.
Fig. 2 is the high-efficient liquid phase chromatogram of rutin and zeaxanthin in the tablet.
The specific embodiment
Realize that below example just is used for the embodiment that the present invention is possible is described, rather than place restrictions on scope of the present invention.
Embodiment one contains the thin membrane coated tablet of rutin and zeaxanthin
Vitamin C 60-120mg
Vitamin A 3000-4000IU
Vitamin E 30-60IU
Rutin or rutin ester 5-25mg
Zeaxanthin and zeaxanthin ester 1-5mg
Zinc 15mg
Copper 2mg
Vitacel 90mg
Dextrose 250-350mg
Stearic acid 8.0mg
Magnesium stearate 3.0mg
Embodiment two contains the thin membrane coated tablet of rutin, zeaxanthin, Semen Cassiae, Flos Chrysanthemi.
Remove the vitamin A among the embodiment one, add Semen Cassiae, each 10mg of Flos Chrysanthemi ethanol extraction.
Embodiment three contains the thin membrane coated tablet of rutin, zeaxanthin, Semen Cassiae, Fructus Lycii.
Remove the vitamin A among the embodiment one, add Semen Cassiae, each 10mg of Fructus Lycii ethanol extraction.
Embodiment four contains the thin membrane coated tablet of rutin, zeaxanthin, Semen Cassiae, Fructus Atriplicis Sibiricae.
Remove the vitamin A among the embodiment one, add Semen Cassiae, each 10mg of Fructus Atriplicis Sibiricae ethanol extraction.
Embodiment five contains the thin membrane coated tablet of rutin, zeaxanthin, Fructus Lycii, Flos Chrysanthemi.
Remove the vitamin A among the embodiment one, add Fructus Lycii, each 10mg of Flos Chrysanthemi ethanol extraction.
Embodiment six contains the thin membrane coated tablet of rutin, zeaxanthin, Fructus Lycii, Fructus Atriplicis Sibiricae.
Remove the vitamin A among the embodiment one, add Fructus Lycii, each 10mg of Fructus Atriplicis Sibiricae ethanol extraction.Embodiment seven contains the thin membrane coated tablet of rutin, zeaxanthin, Flos Chrysanthemi, Fructus Atriplicis Sibiricae.Remove the vitamin A among the embodiment one, add Flos Chrysanthemi, each 10mg of Fructus Atriplicis Sibiricae ethanol extraction.Embodiment eight contains the thin membrane coated tablet of rutin, zeaxanthin and glutathion
Vitamin C 60-120mg
Vitamin A 3000-4000IU
Vitamin E 30-60IU
Rutin or rutin ester 5-25mg
Zeaxanthin or zeaxanthin ester 1-5mg
Zinc 15mg
Copper 2mg
Selenium 20mcg
Manganese 5mg
L-glutathion 5mg
Vitecel 90mg
Dextrose 250-350mg
Stearic acid 8.0mg
Magnesium stearate 3.0mg embodiment nine contains how little multidimensional chew tablet of rutin and zeaxanthin
Vitamin C 60-120mg
Vitamin A 3000-4000IU
Vitamin E 30-60IU
Rutin 5-25mg
Zeaxanthin 1-5mg
Essence 2.0-2.5mg
Pigment 1.0-2.0mg
Zinc 15mg
Copper 2mg
Vitecel 90mg
Dextrose 350mg
Stearic acid 8.0mg
Magnesium stearate 3.0mg embodiment ten contains the soft capsule of rutin and zeaxanthin
Vitamin C 60-120mg
Vitamin E 30-60IU
Rutin 5-25mg
Zeaxanthin 1-5mg
Phosphatidase 12 5mg
Oleum Glycines 75mg embodiment 11 contains the eye drop of rutin and zeaxanthin
Rutin 5-20mg
Zeaxanthin 1-4mg
Oleum Glycines 100mg
Phosphatidase 11 mg
Glycerol 20mg
PH regulator agent (HCl or NaOH) is an amount of
Water for injection 1000mg embodiment 12 contains the eye ointment of rutin and zeaxanthin
Rutin 5-20mg
Zeaxanthin 1-4mg
Vaseline 800mg
Mineral oil 200mg
Vegetable oil 2mg
Claims (15)
1, a class is used for the prevention of oculopathy such as relevant cataract of age, macula lutea decline and the eye nutrient prescription of treatment, it is characterized in that containing in this prescription rutin and zeaxanthin.
2, the using method of the eye nutrient prescription of a kind of prevention that is used for oculopathy such as relevant cataract of age, macula lutea decline and treatment; it is characterized in that providing the rutin of q.s or/and zeaxanthin by oral or topical or other route of administration; with rutin in the lifting blood or/and the concentration of zeaxanthin; to being equal to or higher than the macula retinae rutin or/and zeaxanthin deposits needed level; and kept for 4 to 8 weeks;, can suspend or use than low dosage and kept or/and after zeaxanthin concentration returns to expected value when rutin in the macula lutea.
3, method according to claim 2, it is characterized in that every day used rutin or/and the accumulated dose of zeaxanthin between 1.0mg to 50mg.
4, method according to claim 2, it is characterized in that every day used rutin or/and the accumulated dose of zeaxanthin between 2.0mg to 25mg.
5, method according to claim 2 is characterized in that about 5: 1 of the ratio of rutin and zeaxanthin.
6, method according to claim 2, it is characterized in that take rutin every day or/and the accumulated dose of zeaxanthin by per kilogram of body weight between the 0.05mg to 5mg.
7, method according to claim 2 is characterized in that rutin or/and zeaxanthin is free type, or corresponding ester.
8, prescription according to claim 1 is characterized in that the rutin in this prescription or/and zeaxanthin is pharmaceutical formulation or health product or fast-food type functional food.
9, prescription according to claim 8, it is characterized in that this prescription be a kind of by rutin or/and zeaxanthin or/and its ester and other are medicinal or food with the mixture of raw material, adjuvant or carrier.
10, prescription according to claim 8 is characterized in that containing a kind of antioxidant at least at pharmaceutical formulation or health product or fast-food type functional food.
11, prescription according to claim 8, it is characterized in that this prescription for loose the side or with unit dosage form for use.
12, prescription according to claim 10, it is characterized in that antioxidant be vitamin A or/and vitamin C or/and vitamin E or/and Semen Cassiae or/and Flos Chrysanthemi or/and Flos Chrysanthemi Indici or/and Fructus Lycii or/and Fructus Atriplicis Sibiricae or/and Herba Spinaciae.
13, prescription according to claim 10 is characterized in that described antioxidant is for referring to except that rutin or/and other carotenoid the zeaxanthin.
14, prescription according to claim 13, it is characterized in that other carotenoid be lycopene or/and α carotene or/and bata-carotene or/and γ carotene or/and δ carotene.
15, prescription according to claim 11 is characterized in that unit dosage form is the fast food functional food of tablet or capsule or drop or pill or powder or unguentum or cream or solution or suspensoid or opacifiers or injection or implant or patch or liniment or spray or arbitrary form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021485887A CN1481804A (en) | 2002-12-17 | 2002-12-17 | Eye nutrients formulation for prevention and cure of age-related cataract, macula lutea degradation and other eye disease , and its application method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021485887A CN1481804A (en) | 2002-12-17 | 2002-12-17 | Eye nutrients formulation for prevention and cure of age-related cataract, macula lutea degradation and other eye disease , and its application method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1481804A true CN1481804A (en) | 2004-03-17 |
Family
ID=34148750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA021485887A Pending CN1481804A (en) | 2002-12-17 | 2002-12-17 | Eye nutrients formulation for prevention and cure of age-related cataract, macula lutea degradation and other eye disease , and its application method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1481804A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006002735A1 (en) * | 2004-06-29 | 2006-01-12 | Dsm Ip Assets B.V. | Improvement of image quality in the eye |
| CN100344240C (en) * | 2005-09-07 | 2007-10-24 | 辽宁省农业科学院作物研究所 | Nutrient food capable of preventing cataract and muscae volitantes and its making process |
| JP2008530044A (en) * | 2005-02-11 | 2008-08-07 | ディーエスエム アイピー アセッツ ビー．ブイ． | Use of zeaxanthin for the treatment of peripheral retinal disease |
| CN102202659A (en) * | 2008-11-03 | 2011-09-28 | 朱利亚尼股份公司 | Therapeutic, dietary, or cosmetic use of compounds with specific anti-apoptotic activity toward caspase-3, and compositions containing these compounds |
| CN102781435A (en) * | 2009-12-14 | 2012-11-14 | 固普昂有限公司 | Combination of carotenoids and epi-lutein |
| CN103070877A (en) * | 2012-12-26 | 2013-05-01 | 陈阳 | Vision care drug |
| WO2014023082A1 (en) * | 2012-08-08 | 2014-02-13 | 浙江医药股份有限公司新昌制药厂 | Composition used for improving macular pigment density in eyes and preventing or treating age-related macular degeneration |
| CN103798808A (en) * | 2012-11-15 | 2014-05-21 | 中国科学院大连化学物理研究所 | Nutrient formula and application thereof to food or medicine for reliving asthenopia |
-
2002
- 2002-12-17 CN CNA021485887A patent/CN1481804A/en active Pending
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006002735A1 (en) * | 2004-06-29 | 2006-01-12 | Dsm Ip Assets B.V. | Improvement of image quality in the eye |
| JP2008505137A (en) * | 2004-06-29 | 2008-02-21 | ディーエスエム アイピー アセッツ ビー．ブイ． | Improved eye image quality |
| JP2008530044A (en) * | 2005-02-11 | 2008-08-07 | ディーエスエム アイピー アセッツ ビー．ブイ． | Use of zeaxanthin for the treatment of peripheral retinal disease |
| CN100344240C (en) * | 2005-09-07 | 2007-10-24 | 辽宁省农业科学院作物研究所 | Nutrient food capable of preventing cataract and muscae volitantes and its making process |
| CN102202659A (en) * | 2008-11-03 | 2011-09-28 | 朱利亚尼股份公司 | Therapeutic, dietary, or cosmetic use of compounds with specific anti-apoptotic activity toward caspase-3, and compositions containing these compounds |
| AU2009319185B2 (en) * | 2008-11-03 | 2013-11-14 | Giuliani S.P.A. | Therapeutic, dietary, or cosmetic use of compounds with specific anti-apoptotic activity toward caspase-3, and compositions containing these compounds |
| CN102781435A (en) * | 2009-12-14 | 2012-11-14 | 固普昂有限公司 | Combination of carotenoids and epi-lutein |
| CN102781435B (en) * | 2009-12-14 | 2017-08-08 | 固普昂有限公司 | The combination of carotenoid and (3R,3'S,6'R)-lutein |
| WO2014023082A1 (en) * | 2012-08-08 | 2014-02-13 | 浙江医药股份有限公司新昌制药厂 | Composition used for improving macular pigment density in eyes and preventing or treating age-related macular degeneration |
| CN103798808A (en) * | 2012-11-15 | 2014-05-21 | 中国科学院大连化学物理研究所 | Nutrient formula and application thereof to food or medicine for reliving asthenopia |
| CN103070877A (en) * | 2012-12-26 | 2013-05-01 | 陈阳 | Vision care drug |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7887847B2 (en) | Nutritional supplement for treatment of ocular diseases | |
| EP2883544B1 (en) | Composition used for improving macular pigment density in eyes and preventing or treating age-related macular degeneration | |
| CN108157568A (en) | A kind of Combined candy for alleviating visual fatigue and its preparation method and application | |
| CN1686547A (en) | Long time use compound preparation for treating diabetes | |
| CN102144780A (en) | Lutein ester health care product for protecting eyesight and preparation method thereof | |
| MX2008004981A (en) | Compositions for treatment of eye diseases. | |
| TW200843725A (en) | Organic compounds | |
| WO2014155189A1 (en) | Neuroprotective effect of carotenoids in brain | |
| JP7377283B2 (en) | A method for producing a herbal confectionery that protects the eyes and improves vision, containing nutrients for the human eye's lens and retinal photosensitive cells. | |
| CN108498495A (en) | Retinal pigment degeneration is treated using N-acetylcysteine amide | |
| CN102178925A (en) | Novel eyesight protective agent lutein ophthalmic preparation | |
| CN102753163B (en) | Composition comprising as active ingredient l-carnitine in combination with hydroxykynurenine-o-beta-dl-glucoside, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation | |
| CN107837288A (en) | A kind of compound anthocyanidin lutein ester soft capsule for alleviating visual fatigue | |
| CN1481804A (en) | Eye nutrients formulation for prevention and cure of age-related cataract, macula lutea degradation and other eye disease , and its application method | |
| CN111686208B (en) | Medicine and food dual-purpose composition for resisting blue light injury of retina and preparation method and application thereof | |
| CN1426812A (en) | Relaxation of Climacteric syndrome by using antisenility action of glossy ganoderma | |
| CN104436156A (en) | Eyesight protective agent xanthophyll eye preparation and preparation process thereof | |
| CN1895275A (en) | Calf-blood deprotein extract gel | |
| CN1915337A (en) | Capsule of eye protector for patient of diabetes | |
| CN1478505A (en) | Capsule for delayed senility and its manufacturing method | |
| US20230210801A9 (en) | Compositions for improving eye health and methods of making and using thereof | |
| CN1255167C (en) | Anti-oxidation health care nutrient oil | |
| CN1889961A (en) | Superoxide dismutase mimics for the treatment of optic nerve and retinal damage | |
| CN113057951B (en) | Application of biphenyl lignan compound in preparing medicine for preventing and treating amyotrophic lateral sclerosis | |
| CN1290543C (en) | Medicinal health protection product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20040317 |